Phase II trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone]-rituximab augmented with granulocyte-macrophage colony stimulating factor (GM-CSF [sargramostim]) in patients with previously untreated diffuse large B cell non-Hodgkin's lymphoma

Trial Profile

Phase II trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone]-rituximab augmented with granulocyte-macrophage colony stimulating factor (GM-CSF [sargramostim]) in patients with previously untreated diffuse large B cell non-Hodgkin's lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Sargramostim; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jul 2011 Planned end date changed from 1 Dec 2008 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top